Table 1.

Patient and sample characterization

Tumor characteristicsTumor analysisCSF sample
Patient IDSexAgeDiagnosticLocationDistance to ventricle (≤5 mm)Vol. (cm3)IDH1/IDH2AS/ddPCRATRX ASTP53 mutation AS/ddPCRTERT AS/ddPCRSource(ng/mL) CSFCSF mutationsAS/ddPCR
1M78GBM IDH wtTemporalYes65.9WTWTWTC228T:WT/43%Lumbar103.7T C228T:100% (AS)
2M57GBM IDH wtTemporalYes14.3WTWTWTC228T:79%/43.8%Cisterna M560T C228T:WT/0.23%
3F65GBM IDH wtTemporalYes47.5WTWTWTC228T:73%(ddPCR)Lumbar64.4T C228T:75%(ddPCR)
4F57GBM IDH wtTemporalYes23.47WTWTWTC250T:WT/9%Lumbar35.1T C250T:WT/3.2%
5F81GBM IDH wtParietalNo2WTWTWTC250T:WT/3%Lumbar17.2T C250T:WT/1.7%
6M66GBM IDH wtOccipitalYes98WTC250T:26%(ddPCR)Lumbar13.2T C250T:4%(ddPCR)
7M60GBM IDH wtTemporalYes7.4WTWT17.24%/24.5%C228T:46%(ddPCR)Lumbar9.9T C228T:85%(ddPCR)
8M52GBM IDH wtFrontalYes31.8WTWTWTC250T:27.7%/41%Lumbar5.4T C250T:25%(ddPCR)
9M68GliosarcomaFronto-parietalNo23.5WTWT28.92%/26.7%C250T:5.66%/17.6%Lumbar3.6T C250T:3%(ddPCR)
10F34GBM IDH mutFrontalYes70.33IDH1 R132H: 4.64%/6,6%7.33%10.70% (AS)WTLumbar44.8IDH1 R132H: 12.4%/20% ATRX:14.9%(AS) TP53:28.2%(AS)
11F36Anaplastic astrocytomaInsularYes45.02IDH1 R132S: 43.71%/41%68.77%50% (AS)WTLumbar48.9IDH1 R132S: 45.1%/46% ATRX:68%(AS) TP53:49%(AS)
12F9Anaplastic astrocytomaGliomatosisYes190IDH2 R172W: 8.87% (AS)11.30%11.70%/14.5%C250T:17%(ddPCR)Ventricular4.6IDH2:8.87%(AS) ATRX:11.3%(AS) TP53:11.7%(AS)
13M32Diffuse astrocytomaTemporalYes97.27IDH1 R132H: 25.06%/35.7%70.84%27.32%/32.3%WTLumbar9.0WT
14M34OligodendrogliomaInsularNo58.97IDH1 R132H: 28.9%/31.2%WTWTC228T:41%/67%Lumbar8.7IDH1 R132H: 6%(ddPCR)
15F61OligodendrogliomaParietalNo4.8IDH1 R132H: 11.85%(AS)WTWTC250T:15%/25.7%Cisterna M152.3WT
16F48OligodendrogliomaFrontalYes42.9IDH2 R172K: 18.5%/21.5%WT40.45% (AS)C250T: 14.7%(ddPCR)Lumbar7.25TP53:3% (AS) IDH2:17%(ddPCR) T C250T:7%(ddPCR)
17M44OligodendrogliomaCingulateYes33.1IDH1 R132H: 37.6%/32%WTWTC250T:12.5%/35%Lumbar4.2WT
18M34Diffuse midline gliomaBulbo-medularYes14.5Lumbar7.25H3F3A K27M: 7.3%(ddPCR)
19M16Diffuse midline gliomaThalamusYes20.1Lumbar4.785H3F3A K27M: 17.3%(ddPCR)
20M7Diffuse midline gliomaBulboYes17Lumbar37.54H3F3A K27M: 7%(ddPCR)
  • Abbreviations: AS, amplicon sequencing; ddPCR, droplet digital PCR; Vol., tumor volume.